



Resequencing the Genome of *Bifidobacterium breve* Strain CECT7263

Noelia Martínez,^{a*} Roberto Luque,^b Mónica M. Olivares,^b Abelardo Margolles,^a Oscar Bañuelos^b

Dairy Research Institute of Asturias, Spanish National Research Council (IPLA-CSIC), Villaviciosa, Asturias, Spain^a; Research Department, Biosearch S.A., Granada, Spain^b

ABSTRACT The probiotic properties of *Bifidobacterium breve* CECT7263, as well as its safety, have been the focus of in several studies since 2008, including the sequencing of its genome in 2012. This study aims to complete the available genomic data to deepen the knowledge of some phenotypic characteristics of this strain.

B *Bifidobacterium breve* is one of the bacterial species usually recognized as probiotics. Its presence in the gut flora, and therefore its consumption, is associated with benefits in several aspects of the health of the host (1), which is why there is an increasing number of food products containing bifidobacteria, mainly in the field of dairy and infant nutrition (2). The assertion of safety of probiotic strains requires the determination of their susceptibility to antibiotics and the characterization of possible mechanisms of resistance (3).

Preliminary studies showed that *B. breve* CECT7263 was resistant to three clinically relevant antibiotics: streptomycin, clindamycin, and erythromycin (4). Analysis of the genome sequences published in 2012, grouped in 34 contigs ([5]; GenBank accession no. AFVV00000000) revealed a point mutation in the *rspL* gene, which is involved in streptomycin resistance in other *Bifidobacterium* strains (6). However, no gene related to erythromycin and/or clindamycin resistance was identified after revision of the available DNA sequences. At this point, we decided to perform a new *de novo* sequencing and genome annotation study.

The new draft genome sequence of *B. breve* CECT7263 was determined using a 251-bp paired-end library with Illumina MiSeq technology (Illumina, USA) at Gen-Probio SRL (Parma, Italy). A total of 423,772 reads were generated and assembled into 25 contigs using MIRA version 4.0.2 and the following tools in order to refine the final sequences: the Burrows–Wheeler aligner, SAMtools suite, VarScan version 2.2.3, and GATK software package version 2.8-1. Offline open reading frame (ORF) prediction was performed with Prodigal version 2.6 and its automatic annotation by means of a BLAST comparison against the NCBI databases and HMMER against the PFAM database. To identify sequences corresponding to rRNA and tRNA genes, RNAmmer version 1.2 and tRNAscan-SE version 1.21 were employed, respectively. The new draft genome sequence is composed of 2,330,408 bp, which contains 1,951 ORFs (2,314,396 and 1,868 ORFs in the previous genome sequence) and a G+C content of 58.9%. *In silico* analyses with genome sequence revealed the absence of plasmid replicon sequences (7), supporting previous empirical results (data not shown).

A search performed with the genome sequences obtained in this study in antibiotic resistance databases (8) did not detect putative genes involved in erythromycin and clindamycin resistance. Further studies must be conducted in order to know what genetic sequences encode the erythromycin/clindamycin resistance phenotype in *B. breve* CECT7263.

Received 15 March 2017 Accepted 16 March 2017 Published 4 May 2017

Citation Martínez N, Luque R, Olivares MM, Margolles A, Bañuelos O. 2017. Resequencing the genome of *Bifidobacterium breve* strain CECT7263. *Genome Announc* 5:e00299-17. <https://doi.org/10.1128/genomeA.00299-17>.

Copyright © 2017 Martínez et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Oscar Bañuelos, obanuelos@biosearchlife.com.

* Present address: Noelia Martínez, MicroViable Therapeutics, Asturias, Spain.

Accession number(s). The complete genome sequence has been deposited in GenBank under the accession number [MWVVR000000000](https://www.ncbi.nlm.nih.gov/nuclseq/MWVVR000000000) (BioProject no. PRJNA377846).

ACKNOWLEDGMENTS

This work was supported by a grant from the Agency of Innovation and Development of Andalusia (IDEA-Spain), cofinanced by the European Regional Development Fund (EC), project title: “New applications of probiotic strains and derived compounds with biological activity (POSTBIO).” Roberto Luque, Mónica M. Olivares, and Oscar Bañuelos are employees of Biosearch S.A., company owner of a patent application including *B. breve* CECT7263.

REFERENCES

1. Arbolea S, Watkins C, Stanton C, Ross RP. 2016. Gut bifidobacteria populations in human health and aging. *Front Microbiol* 7:1204. <https://doi.org/10.3389/fmicb.2016.01204>.
2. Chassard C, de Wouters T, Lacroix C. 2014. Probiotics tailored to the infant: a window of opportunity. *Curr Opin Biotechnol* 26:141–147. <https://doi.org/10.1016/j.copbio.2013.12.012>.
3. European Food Safety Authority. 2012. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. *EFSA J* 10:2740.
4. Martín R, Olivares M, Jiménez EA, Marín ML, Sierra S, Maldonado A, Martín V, Blanch F, Torre C, Lara-Villoslada F, Arroyo R, Boza J, Jiménez J, Fernández L, Sobrino OJ, Xaus J, Rodríguez JM, Delgado S. December 2008. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis. European patent EP1997499.
5. Jiménez E, Villar-Tajadura MA, Marín M, Fontecha J, Requena T, Arroyo R, Fernández L, Rodríguez JM. 2012. Complete genome sequence of *Bifidobacterium breve* CECT 7263, a strain isolated from human milk. *J Bacteriol* 194:3762–3763. <https://doi.org/10.1128/JB.00691-12>.
6. Sato T, Iino T. 2010. Genetic analyses of the antibiotic resistance of *Bifidobacterium bifidum* strain Yakult YIT 4007. *Int J Food Microbiol* 137: 254–258. <https://doi.org/10.1016/j.ijfoodmicro.2009.12.014>.
7. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
8. Liu B, Pop M. 2009. ARDB—Antibiotic Resistance Genes Database. *Nucleic Acids Res* 37:D443–D447. <https://doi.org/10.1093/nar/gkn656>.